1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Aspirin: first choice for preventing recurrent stroke? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Ramipril beats conventional therapy for HF in Spain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Abacavir/lamivudine-based regimens effective in first-line use for HIV |
|
Inpharma Weekly,
Volume &NA;,
Issue 1356,
2002,
Page 11-12
Raewyn Poole,
Preview
|
|
摘要:
Regimens containing a nucleoside reverse transcriptase inhibitor (NRTI) backbone of abacavir plus lamivudine are effective in treatment-naive patients with HIV infections who have high baseline viral loads, according to interim results from the CLASS*study presented at the XIV International AIDS Conference [Barcelona, Spain; July 2002]. Although these results suggested that the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz provided greater response rates than regimens containing either the protease inhibitors (PI) amprenavir plus ritonavir or the NRTI stavudine, all three combinations had high response rates.'Our preliminary results suggest that even patients with advanced HIV infection can benefit substantially from currently available therapies',said Dr John Bartlett from Duke University Medical Center in Durham, US.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|